Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells.

2.50
Hdl Handle:
http://hdl.handle.net/10541/94925
Title:
Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells.
Authors:
Ward, Timothy H; Butler, John; Shahbakhti, H; Richards, J T
Abstract:
Two versions of the comet assay have been used to identify the difference in the modes of action of AZQ (2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone) and BZQ (2,5-diaziridinyl-3,6-bis(ethanolamino)-1,4-benzoquinone) in human leukaemia K562 cells and a K562-derived resistant cell line, BZQR. Using the standard alkaline assay, AZQ produced dose-dependent changes in the mean comet moments from K562 cells, consistent with the formation of strand breaks. This damage was repaired over a period of 6 hr after removal of the drug. The resistant cell line, BZQR, showed much smaller changes in comet moment under identical conditions. In contrast to AZQ, BZQ did not produce any measurable strand breaks in the K562 or BZQR cells. However, the comet radiation/crosslinking assay and a fluorescence-based assay revealed that BZQ extensively cross-links DNA in K562 cells. The extent of cross-linking is greatly reduced in the resistant cell line.
Affiliation:
CRC Department of Cell Culture, Paterson Institute for Cancer Research, Christie Hospital, Manchester, U.K.
Citation:
Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells. 1997, 53 (8):1115-21 Biochem. Pharmacol.
Journal:
Biochemical Pharmacology
Issue Date:
25-Apr-1997
URI:
http://hdl.handle.net/10541/94925
PubMed ID:
9175716
Type:
Article
Language:
en
ISSN:
0006-2952
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorWard, Timothy Hen
dc.contributor.authorButler, Johnen
dc.contributor.authorShahbakhti, Hen
dc.contributor.authorRichards, J Ten
dc.date.accessioned2010-03-24T15:56:03Z-
dc.date.available2010-03-24T15:56:03Z-
dc.date.issued1997-04-25-
dc.identifier.citationComet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells. 1997, 53 (8):1115-21 Biochem. Pharmacol.en
dc.identifier.issn0006-2952-
dc.identifier.pmid9175716-
dc.identifier.urihttp://hdl.handle.net/10541/94925-
dc.description.abstractTwo versions of the comet assay have been used to identify the difference in the modes of action of AZQ (2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone) and BZQ (2,5-diaziridinyl-3,6-bis(ethanolamino)-1,4-benzoquinone) in human leukaemia K562 cells and a K562-derived resistant cell line, BZQR. Using the standard alkaline assay, AZQ produced dose-dependent changes in the mean comet moments from K562 cells, consistent with the formation of strand breaks. This damage was repaired over a period of 6 hr after removal of the drug. The resistant cell line, BZQR, showed much smaller changes in comet moment under identical conditions. In contrast to AZQ, BZQ did not produce any measurable strand breaks in the K562 or BZQR cells. However, the comet radiation/crosslinking assay and a fluorescence-based assay revealed that BZQ extensively cross-links DNA in K562 cells. The extent of cross-linking is greatly reduced in the resistant cell line.en
dc.language.isoenen
dc.subjectCultured Tumour Cellsen
dc.subject.meshAntineoplastic Agents-
dc.subject.meshAziridines-
dc.subject.meshBenzoquinones-
dc.subject.meshCross-Linking Reagents-
dc.subject.meshDNA Damage-
dc.subject.meshDNA Repair-
dc.subject.meshDrug Resistance-
dc.subject.meshElectrophoresis, Agar Gel-
dc.subject.meshHumans-
dc.subject.meshTumor Cells, Cultured-
dc.titleComet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Cell Culture, Paterson Institute for Cancer Research, Christie Hospital, Manchester, U.K.en
dc.identifier.journalBiochemical Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.